Neuroendocrine transdifferentiation in human prostate cancer cells: An integrated approach

Cancer Research

Volumn 75, Issue 15, 2015, Pages 2975-2986

  Cerasuolo, Marianna ^a   Paris, Debora ^b   Iannotti, Fabio A ^b   Melck, Dominique ^b   Verde, Roberta ^b   Mazzarella, Enrico ^b   Motta, Andrea ^b   Ligresti, Alessia ^b  

^a UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ALANINE; ANDROGEN; ANDROGEN RECEPTOR; CREATINE; CREATINE PHOSPHATE; G PROTEIN COUPLED RECEPTOR 30; GLYCINE; NEURON SPECIFIC ENOLASE; NEUROTENSIN; PROSTATE SPECIFIC ANTIGEN; TRANSIENT RECEPTOR POTENTIAL CHANNEL M8; CULTURE MEDIUM;

ARTICLE; CELL FUNCTION; CELL POPULATION; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CELL TRANSDIFFERENTIATION; COMPUTER MODEL; CULTURE MEDIUM; HUMAN; HUMAN CELL; LNCAP CELL LINE; MALE; MATHEMATICAL MODEL; METABOLOMICS; NEUROSECRETORY CELL; NONLINEAR SYSTEM; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TRANSCRIPTOMICS; ALGORITHM; CLUSTER ANALYSIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PHARMACOLOGY; POLYMERASE CHAIN REACTION; PROSTATE TUMOR; THEORETICAL MODEL; TUMOR CELL CULTURE;

ALGORITHMS; ANDROGENS; CELL TRANSDIFFERENTIATION; CLUSTER ANALYSIS; CULTURE MEDIA, CONDITIONED; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MODELS, THEORETICAL; PHENOTYPE; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84943158510     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-3830     Document Type: Article

References (41)

1. Adimy M, Crauste F, Marquet C. Asymptotic behavior and stability switch for a mature-immature model of cell differentiation. Nonlinear Anal: Real World Appl 2010;11:2913-29.
2. Adimy M, Crauste F, Ruan S. Modelling hematopoiesis mediatedbygrowth factors with applications toperiodic hematological diseases. Bull Math Biol 2006;68:2321-51.
3. Morken JD, Packer A, Everett RA, Nagy JD, Kuang Y. Mechanisms of resistance to intermittent androgen deprivation in patients with prostate cancer identified by a novel computational method. Cancer Res 2014;74: 3673-83.
4. Portz T, Kuang Y, Nagy J. A clinical data validated mathematical model of prostate cancer growth under intermittent androgen suppression therapy. AIP Adv 2012;2:1-14.
5. Eikenberry SE, Nagy JD, Kuang Y. The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model. Biol Direct 2010;5:24.
6. Terry S, Beltran H. The many faces of neuroendocrine differentiation in prostate cancer progression. Front Oncol 2014;4:1-9.
7. Perrot V. Neuroendocrine differentiation in the progression of prostate cancer: an update on recent developments. Open J Urol 2012;2:173-82.
8. Bonkhoff H. Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. Ann Oncol 2001;12 Suppl 2:S141-4.
9. Hansson J, Abrahamsson PA. Neuroendocrine pathogenesis in adenocarcinoma of the prostate. Ann Oncol 2001;12 Suppl 2:S145-52.
10. Berruti A, Vignani F, Russo L, Bertaglia V, Tullio M, Tucci M, et al. Prognostic role of neuroendocrine differentiation in prostate cancer, putting together the pieces of the puzzle. Open Access J Urol 2010;2:109-24.
11. Taplin ME. Secondary hormone therapy for castration-resistant prostate cancer. Oncology (Williston Park) 2013;27:371-2.
12. Beltran H, Tagawa ST, Park K, MacDonald T, Milowsky MI, Mosquera JM, et al. Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol 2012;30:e386-9.
13. Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 2009;15:4792-8.
14. Kollermann J, Helpap B. Neuroendocrine differentiation and short-term neoadjuvant hormonal treatment of prostatic carcinoma with special regard to tumor regression. Eur Urol 2001;40:313-7.
15. Jiborn T, Bjartell A, Abrahamsson P. Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. Urology 1998;51:585-9.
16. Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 2004;45:586-92; discussion 592.
17. Xia J, Mandal R, Sinelnikov IV, Broadhurst D, Wishart DS. MetaboAnalyst 2.0 - a comprehensive server for metabolomic data analysis. Nucleic Acids Res 2012;40 (Web Server issue):W127-33.
18. Xia J, Psychogios N, Young N, Wishart DS. MetaboAnalyst: a web server for metabolomic data analysis and interpretation. Nucleic Acids Res 2009;37 (Web Server issue):W652-60.
19. Jackson T. A mathematical model of prostate tumor growth and androgen-independent relapse. Discrete Continuous Dynam Syst Ser B 2004;4: 187-202.
20. Tao Y, Guo Q, Aihara K. A partial differential equation model and its reduction to an ordinary differential equation model for prostate tumor growth under intermittent hormone therapy. JMath Biol 2014;69:817-38.
21. Ideta A, Tanaka G, Takeuchi T, Aihara K. A mathematical model of intermittent androgen suppression for prostate cancer. J Nonlinear Sci 2008;18:593-613.
22. Hirata Y, Bruchovsky N, Aihara K. Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer. J Theor Biol 2010;264:517-27.
23. Tao Y, Guo Q, Aihara K. A model at the macroscopic scale of prostate tumor growth under intermittent androgen suppression. Math Models Methods Appl Sci 2009;19:2177-201.
24. Guo Q, Tao Y, Aihara K. Mathematical modeling of prostate tumor growth under intermittent androgen suppression with partial differential equations. Int J Bifurc Chaos 2008;18:3789-96.
25. Tanaka G, Hirata Y, Goldenberg S, Bruchovsky N, Aihara K. Mathematical modelling of prostate cancer growth and its application to hormone therapy. Philos Trans A Math Phys Eng Sci 2010;368:5029-44.
26. Di Garbo A, Johnston M, Chapman S, Maini P. Variable renewal rate and growth properties of cell populations in colon crypts. Phys Rev E Stat Nonlin Soft Matter Phys 2010;104:4008-13.
27. d'Onofrio A, Tomlinson I. A nonlinear mathematical model of cell turnover differentiation and tumorigenesis in the intestinal crypt. J Theor Biol 2007;244:367-74.
28. Johnston M, Edwards C, Bodmer W, Maini P, Chapman S. Mathematical modeling of cell population dynamics in the colonic crypt and in colorectal cancer. Proc Natl Acad Sci U S A 2007;104:4008-18.
29. Sottoriva A, Sloot P, Medema J, Vermeulen L. Exploring cancer stem cell niche directed tumor growth. Cell Cycle 2010;9:1472-9.
30. Quinn T, Sinkala Z. Dynamics of prostate cancer stem cells with diffusion and organism response. Biosystems 2009;96:69-79.
31. McDunn JE, Li Z, Adam KP, Neri BP, Wolfert RL, Milburn MV, et al. Metabolomic signatures of aggressive prostate cancer. Prostate 2013;73: 1547-60.
32. Yue S, Li J, Lee SY, Lee HJ, Shao T, Song B, et al. Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. Cell Metab 2014;19:393-406.
33. Wang Q, Horiatis D, Pinski J. Inhibitory effect of IL-6-induced neuroendocrine cells on prostate cancer cell proliferation. Prostate 2004;61: 253-9.
34. Yuan TC, Veeramani S, Lin MF. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer 2007;14:531-47.
35. Tessem M, Swanson M, Keshari K, Albers M, Joun D, Tabatabai Z, et al. Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsytissues. Magn Reson Med 2008;60:510-6.
36. Weinstein SJ, Mackrain K, Stolzenberg-Solomon RZ, Selhub J, Virtamo J, Albanes D. Serum creatinine and prostate cancer risk in a prospective study. Cancer Epidemiol Biomarkers Prev 2009;18:2643-9.
37. Khan AP, Rajendiran TM, Ateeq B, Asangani IA, Athanikar JN, Yocum AK, et al. The role of sarcosine metabolism in prostate cancer progression. Neoplasia 2013;15:491-501.
38. Munoz-Pinedo C, El Mjiyad N, Ricci JE. Cancer metabolism: current perspectives and future directions. Cell Death Dis 2012;3:e248.
39. Serkova NJ, Gamito EJ, Jones RH, O'Donnell C, Brown JL, Green S, et al. The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions. Prostate 2008;68:620-8.
40. Traverso N, Ricciarelli R, Nitti M, Marengo B, Furfaro AL, Pronzato MA, et al. Role of glutathione in cancer progression and chemoresistance. Oxid Med Cell Longev 2013;2013:972913.
41. Lao L, Franklin RB, Costello LC. High-affinity L-aspartate transporter in prostate epithelial cells that is regulated by testosterone. Prostate 1993; 22:53-63.